Hyperion DeFi Posts Record Q2 Net Income of $31.0M and $53.7M Adjusted EBITDA
HYPD sits 19% above its 52-week low of $2.34 on light trading volume (0.2× avg).
Summary
Record Q2 2026 results for Hyperion DeFi included net income of $31.0 million and Adjusted EBITDA of $53.7 million, driven by HYPE token price gains. The company also announced a new HAUS partnership with Entropy and completed the sale of its legacy life sciences IP.
Key Events · Earnings and Guidance · HYPD
-
Record Q2 Net Income
Net income of $31.0 million marked a second consecutive record quarter, up from $8.8 million in Q1 2026. Adjusted EBITDA came in at $53.7 million versus $19.5 million in Q1 2026.
-
Treasury Gains Drive Earnings
Treasury gains of $54.8 million in Q2 2026 were driven by HYPE token price appreciation to $65.0 from $36.6 at the end of Q1 2026. Gross HYPE Holdings increased to $132.6 million.
-
New HAUS Partnership with Entropy
A HAUS agreement was announced with Entropy, an upcoming HIP-3 deployer, deploying 500,000 staked HYPE tokens. This follows the Skew partnership announced in July 2026.
-
Legacy Biotech Wind-Down Completed
All remaining legacy life sciences IP was sold to Arctic Vision in July 2026 in exchange for release of indebtedness. Cumulative liability releases from the biotech wind-down exceed $2.7 million.
Analysis · HYPD · Life Sciences
A second consecutive record quarter underscores the momentum behind Hyperion DeFi's digital asset pivot. Net income reached $31.0 million, up from $8.8 million in Q1 2026, propelled by a $54.8 million treasury gain as HYPE token prices climbed to $65.0 during the quarter. The company also unveiled a new HAUS partnership with Entropy, deploying 500,000 staked HYPE, and completed the sale of its remaining legacy life sciences IP to Arctic Vision. Management reiterated 2026 Adjusted Gross Profit guidance of $5 million to $7 million, roughly 5x 2025 results, and expects Adjusted Net Operating Cash Flow to turn positive by year-end. While the results demonstrate that the treasury model is generating substantial earnings, the income remains heavily dependent on HYPE token price appreciation.
At the time of this filing, HYPD was trading at $2.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $2.34 to $15.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.